Tricetyl fingolimod is primarily used in the treatment of multiple sclerosis (MS), particularly the relapsing forms of the disease. It functions by modulating the sphingosine-1-phosphate receptor, which reduces the migration of harmful immune cells into the central nervous system. This action helps decrease the frequency of clinical relapses and slows the progression of physical disability. The compound improves patient outcomes by maintaining immune surveillance while limiting autoimmune attacks on neural tissues. Due to its oral bioavailability, it offers a convenient alternative to injectable therapies, enhancing long-term treatment adherence. It may also be investigated for potential use in other autoimmune conditions and neuroinflammatory disorders.